"Drug Industry" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
| Descriptor ID |
D004345
|
| MeSH Number(s) |
J01.576.655.750
|
| Concept/Terms |
Drug Industry- Drug Industry
- Industry, Pharmaceutic
- Industries, Pharmaceutic
- Pharmaceutic Industries
- Pharmaceutic Industry
- Industry, Drug
- Drug Industries
- Industries, Drug
- Industry, Pharmaceutical
- Industries, Pharmaceutical
- Pharmaceutical Industries
- Pharmaceutical Industry
|
Below are MeSH descriptors whose meaning is more general than "Drug Industry".
Below are MeSH descriptors whose meaning is more specific than "Drug Industry".
This graph shows the total number of publications written about "Drug Industry" by people in this website by year, and whether "Drug Industry" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 0 | 3 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 2 | 4 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 3 | 1 | 4 |
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 2 | 5 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 2 | 5 |
| 2012 | 0 | 1 | 1 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Industry" by people in Profiles.
-
Humira: the first $20 billion drug. Am J Manag Care. 2023 02; 29(2):78-80.
-
Policing of Drug Safety Information Dissemination Under the False Claims Act. Cancer Treat Res. 2022; 184:53-59.
-
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
-
Biosimilars-Curb Your Enthusiasm. JAMA Oncol. 2017 11 01; 3(11):1467-1468.
-
Why California's Proposition 61 Was a Bad Idea. Am J Med. 2017 08; 130(8):882-884.
-
Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door. J Clin Oncol. 2016 12 20; 34(36):4320-4322.
-
Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment. JAMA Oncol. 2016 Feb; 2(2):274-6.
-
Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.
-
A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report. J Oncol Pract. 2012 Nov; 8(6):e158-67.
-
The gastroenterologist and industry: changing winds. Gastrointest Endosc Clin N Am. 2012 Jan; 22(1):121-34.